Primary non-hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II

2004 ◽  
Vol 59 (3) ◽  
pp. 760-764 ◽  
Author(s):  
Enza Barbieri ◽  
Silvia Cammelli ◽  
Floranna Mauro ◽  
Francesco Perini ◽  
Alberto Cazzola ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Stage I ◽  
Stage Ii ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Prognostic Factors in Stage I and II Non-Hodgkin's Lymphoma of Waldeyer's Ring

1985 ◽  
Vol 24 (2) ◽  
pp. 153-158 ◽  
Author(s):  
M. Kondo ◽  
A. Mikata ◽  
K. Ogawa ◽  
Y. Inuyama ◽  
Y. Murakami ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Waldeyer’S Ring ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma

1988 ◽  
Vol 24 (10) ◽  
pp. 1617-1622 ◽  
Author(s):  
J.F. Mackintosh ◽  
R.A. Cowan ◽  
M. Jones ◽  
M. Harris ◽  
D.P. Deakin ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Intermediate Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract.

1988 ◽  
Vol 6 (2) ◽  
pp. 253-260 ◽  
Author(s):  
F A Shepherd ◽  
W K Evans ◽  
G Kutas ◽  
J C Yau ◽  
P Dang ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Hodgkin’S Lymphoma ◽  
Residual Disease ◽  
Systemic Disease ◽  
Stage I ◽  
Stage Ii ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Complete Surgical Resection ◽  
Non Hodgkin's Lymphoma

Twenty-six patients were treated with chemotherapy following surgery for gastrointestinal non-Hodgkin's lymphoma (GI-NHL). The median age was 50 years (range, 20 to 76). The primary site included stomach (16 patients), small bowel (seven), large bowel (two), and mesenteric nodes (one). Following surgery, nine patients had macroscopic and four patients had microscopic residual disease, and 13 were felt to have had complete surgical resection. Thirteen patients were stage I and 13 were stage II. Sixteen patients were treated with COPP (cyclophosphamide, vincristine, procarbazine, prednisone), nine with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and one with CVP (cyclophosphamide, vincristine, prednisone). At a median follow-up of 50 months (8+ to 178+ months) ten of 12 stage I patients and nine of 14 stage II patients remain alive. Of the nine patients with macroscopic residual disease, four died of disease 6.5 to 11.0 months after diagnosis, and five are alive 8+ to 178+ months from diagnosis. Fourteen of the remaining 17 patients who had complete surgical resection are alive without disease. Death in the other three patients was due to multiple abdominal abscesses at 12 months, adenocarcinoma of the colon at 57 months, and dementia and progressive neurologic dysfunction at 65 months. No patient who had complete resection has relapsed or developed systemic disease after chemotherapy. These results suggest that complete surgical resection is an important prognostic factor and that chemotherapy without irradiation in completely resected localized GI-NHL can prevent local and systemic relapse resulting in long-term disease-free survival.

Extranodal Non-Hodgkin’s Lymphoma. A Study of 182 Patients with Analysis of Prognostic Factors.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4557-4557
Author(s):  
Enrico Maria Pogliani ◽  
Fausto Rossini ◽  
Veronica Coccini ◽  
Alessandra Larocca ◽  
Luisa Verga ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Complete Remission ◽  
Head And Neck ◽  
Hodgkin’S Lymphoma ◽  
Stage I ◽  
Stage Ii ◽  
Hodgkin's Lymphoma ◽  
Stage Iii ◽  
Non Hodgkin's Lymphoma

Abstract Starting from 1980, 182 cases of primary extranodal non-Hodgkin’s lymphoma were diagnosed in our Division. Gastrointestinal NHL were the most frequent: 66 patients (36%), followed by head and neck (42 = 23%), skin(23 =13%), urogenital tract (16 = 9%), CNS (10 =5%), chest (9 = 5%), spleen (7 = 4%), bone (5 = 3%) soft tissues (4 = 2%). Median age was 55,4 (range 20–91); median age was lower in chest, bone and intestinal NHL. 77 patients had stage I disease (48,8%), 74 stage II (46,5%) and 8 patients stage III (5%). In the whole group, 134/182 (73.6%) patients achieved complete remission (CR); CRs were 81.8% in gastroenteric NHL, 75% in urogenital, 69.5% in skin, 66.6% in head and neck. Overall survival in the two most important groups are as follows: head and neck: 61% at 50 months and 55% at 100 months; gastrointestinal tract: at 50 months was 80%, at 100 months 75%. When prognostic factors were considered for the whole group, stage and modified I.P.I. (MIPI) were significantly associated with rate of complete remission and overall survival. Stage I pts had a significantly better rate of complete remission 83.1%, vs. 68.9% for stage II and 37.5% for stage III. Overall survival of stage I pts was significantly better than for patients with stage II or stage III disease (80% vs. 72.5% at 50 months; 80.1% vs. 62.7% at 100 months). Modified International Prognostic Index, MIPI is a score ranging from 0 to 5 according to age (>60), LDH (over normal values), ECOG P.S. (>1), Ann Arbor stage (II or III), extranodal sites (>1). Thirty six patients had a MIPI score of 0, 80 pts MIPI 1, 50 pts MIPI 2 and 16 had a MIPI score of 3 or more. A significant correlation between MIPI and achievement of CR was shown with 88.8% of pts with MIPI 0 achieving CR, 78.5% in MIPI 1, 28% in MIPI 2 and 25% in MIPI 3 or more. Overall survival for the four groups was as follows: 96%, 75%, 62%, 61% at 50 months; 96%, 70%, 54%, 24% at 100 months.

Primary Large-Cell Non-Hodgkin's Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors

2001 ◽  
Vol 2 (2) ◽  
pp. 109-115 ◽  
Author(s):  
John F. Seymour ◽  
Benjamin Solomon ◽  
Max M. Wolf ◽  
E. Henry Janusczewicz ◽  
Andrew Wirth ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Hodgkin’S Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Patterns Of Failure ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

1998 ◽  
Vol 16 (1) ◽  
pp. 27-34 ◽  
Author(s):  
U Tirelli ◽  
D Errante ◽  
M Van Glabbeke ◽  
I Teodorovic ◽  
J C Kluin-Nelemans ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Randomized Study ◽  
Objective Response ◽  
Stage Ii ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Standard Regimen ◽  
European Organization ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a chemotherapy regimen specifically devised for elderly patients, ie, etoposide, mitoxantrone, and prednimustine (VMP), versus the standard regimen of cyclophosphamide, doxorobucin, vincristine, and prednisone (CHOP) in patients older than 70 years of age with intermediate- and high-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Patients older than 70 years of age with stage II, III, or IV intermediate- and high-grade NHL, with an Eastern Cooperative Oncology Group (ECOG) performance status less than 4 and acceptable cardiac, renal, and liver function were randomized to receive six courses of VMP or six courses of CHOP. Between February 1989 and June 1994, 130 patients aged 70 to 93 years (median, 75) were enrolled and 120 were assessable for response, 60 patients in each arm. RESULTS Overall objective response rates were 50% and 77% in VMP- and CHOP-treated patients, respectively (P = .01), while complete response (CR) rates were borderline significant (27% v 45%; P = .06). At 2 years, the progression-free survival (PFS) rate was 25% with VMP versus 55% with CHOP (P = .002) and the overall survival (OS) rate was 30% with VMP versus 65% with CHOP (P = .004). Statistically significant more alopecia and neurologic and gastrointestinal toxicities were reported with CHOP. CONCLUSION CHOP is the standard regimen for patients > or = 70 years of age with stage II to IV intermediate- and high-grade NHL.

Sign in / Sign up

Export Citation Format

Share Document